Related Experiment Video
Updated: Jun 11, 2025
12:03
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
17.8K
Angiotensin II-Real-Life Use and Literature Review
Andreja Möller Petrun1,2, Andrej Markota2,3
1Department of Anaesthesiology, Intensive Therapy and Pain Management, University Medical Centre Maribor, 2000 Maribor, Slovenia.
Medicina (Kaunas, Lithuania)
|September 28, 2024
Summary
Angiotensin II, a novel vasopressor, effectively manages shock by activating the renin-angiotensin-aldosterone system. Further research is needed to clarify optimal use, combination strategies, and discontinuation protocols for this important therapeutic agent.
Area of Science:
- Pharmacology and Physiology
- Critical Care Medicine
Background:
- Angiotensin II is a novel vasopressor introduced in 2017, acting via the renin-angiotensin-aldosterone system.
- Its novelty and cost currently limit widespread clinical application.
- It is the only vasopressor that uniquely activates this pathway.
Purpose of the Study:
- To review the physiological and pathophysiological effects of angiotensin II.
- To describe the pharmacology of angiotensin II.
- To provide a narrative review of current literature on angiotensin II in shock management.
Main Methods:
- Literature review of existing studies on angiotensin II.
- Analysis of physiological and pathophysiological mechanisms.
- Pharmacological description of angiotensin II.
Main Results:
- Angiotensin II induces vasoconstriction and affects other physiological processes.
- Evidence supports its use in refractory vasoplegic and cardiogenic shock.
- Optimal timing, combination strategies, and discontinuation protocols remain unclear due to limited data.
Conclusions:
- Angiotensin II is a valuable therapeutic option for specific shock states.
- Further research is required to optimize its clinical application.
- Ongoing studies aim to address current uncertainties regarding its use.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
597
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
597
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
490
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
490
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
395
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
395
01:25Antihypertensive Drugs: Direct Renin Inhibitors
506
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
506
01:29Hypertension II: Pathophysiology
2
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
2
01:29Heart Failure II: Pathophysiology
3
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
3